Kyle Gano Biography and Net Worth

Kyle W. Gano, Ph.D. was appointed Chief Business Development Officer in 2011, and Chief Business Development and Strategy Officer in 2020, and is responsible for all business and corporate development activities, including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma, BIAL, Jnana Therapeutics, Voyager Therapeutics, Xenon Pharmaceuticals, and Idorsia Ltd. From 2001 to 2011, Dr. Gano held several positions of increasing responsibility at Neurocrine Biosciences spanning marketing analytics to business development. Dr. Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A in Finance from the University of California, Los Angeles.

What is Kyle Gano's net worth?: The estimated net worth of Kyle Gano is at least $16.47 million as of January 2nd, 2024. Dr. Gano owns 130,250 shares of Neurocrine Biosciences stock worth more than $16,471,415 as of December 3rd. This net worth estimate does not reflect any other investments that Dr. Gano may own. Additionally, Dr. Gano receives an annual salary of $990,120.00 as Insider at Neurocrine Biosciences. Learn More about Kyle Gano's net worth.
How old is Kyle Gano?: Dr. Gano is currently 51 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Kyle Gano's age.
What is Kyle Gano's salary?: As the Insider of Neurocrine Biosciences, Inc., Dr. Gano earns $990,120.00 per year. There are 4 executives that earn more than Dr. Gano. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $2,050,000.00 per year. Learn More on Kyle Gano's salary.
How do I contact Kyle Gano?: The corporate mailing address for Dr. Gano and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Kyle Gano's contact information.
Has Kyle Gano been buying or selling shares of Neurocrine Biosciences?: Kyle Gano has not been actively trading shares of Neurocrine Biosciences over the course of the past ninety days. Most recently, Kyle Gano sold 75,000 shares of the business's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $131.47, for a transaction totalling $9,860,250.00. Following the completion of the sale, the insider now directly owns 130,250 shares of the company's stock, valued at $17,123,967.50. Learn More on Kyle Gano's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 45 times. They sold a total of 574,605 shares worth more than $78,018,075.30. The most recent insider tranaction occured on August, 15th when Director William H Rastetter sold 14,250 shares worth more than $2,090,332.50. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 8/15/2024.

Kyle Gano Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/2/2024	Sell	75,000	$131.47	$9,860,250.00	130,250
1/5/2022	Sell	28,266	$85.50	$2,416,743.00
2/5/2020	Sell	3,690	$103.05	$380,254.50
2/5/2019	Sell	3,809	$88.12	$335,649.08	17,595
11/2/2017	Sell	24,818	$71.05	$1,763,318.90	84,596
5/1/2017	Sell	15,000	$54.00	$810,000.00	88,246
4/11/2016	Sell	41,770	$44.02	$1,838,715.40	57,788
1/12/2015	Sell	1,250	$28.41	$35,512.50
12/17/2014	Sell	4,957	$22.50	$111,532.50
12/12/2014	Sell	4,043	$22.50	$90,967.50
9/4/2013	Sell	2,400	$15.61	$37,464.00	22,488

Kyle Gano Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $126.46

$125.41

$126.70

50 Day Range

MA: $119.42

$111.62

$127.91

2 Week Range

Now: $126.46

$110.95

$157.98

Volume

149,947 shs

Average Volume

870,869 shs

Market Capitalization

$12.80 billion

P/E Ratio

33.90

Dividend Yield

N/A

Beta

0.34

Could This Tiny Device Help You Make an Extra $30k a Year?

From Brownstone Research | Ad

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Kyle Gano Biography and Net Worth

What is Kyle Gano's net worth?

How old is Kyle Gano?

What is Kyle Gano's salary?

How do I contact Kyle Gano?

Has Kyle Gano been buying or selling shares of Neurocrine Biosciences?

Who are Neurocrine Biosciences' active insiders?

Are insiders buying or selling shares of Neurocrine Biosciences?